Bundibugyo Vaccine Trials Advance to Phase 1 as DRC Outbreak Exposes Ebola Preparedness Gaps
Updated
Updated · STAT · Aug 10
Bundibugyo Vaccine Trials Advance to Phase 1 as DRC Outbreak Exposes Ebola Preparedness Gaps
3 articles · Updated · STAT · Aug 10
Summary
Oxford and the Serum Institute of India have launched the first Phase 1 trial of a Bundibugyo-specific Ebola vaccine, while Moderna has started a separate Phase 1 mRNA candidate.
The push comes during the Democratic Republic of the Congo's largest-ever Ebola outbreak, where tools built mainly for Zaire ebolavirus left gaps in diagnosis, vaccine policy and treatment evidence.
WHO advisers revisited Ervebo on July 31 after early lab and animal data suggested partial cross-protection, recommending a Phase 3 trial in the outbreak without a prior Phase 2 study.
Therapeutic studies are also expanding: the WHO-led PARTNERS trial is testing remdesivir and MBP134, and EBO-PEP is evaluating obeldesivir for high-risk contacts.
The outbreak has become a broader warning that Ebola preparedness needs pan-filovirus diagnostics, broader vaccines and adaptable trial and manufacturing platforms before the next crisis.